History of AtriCure

Since the founding and incorporation of AtriCure, the commitment to innovation has been relentless.


Michael Hooven and his wife, Sue Spies, co-founded ENABLE Medical Corporation. ENABLE Medical’s first product was a pair of radiofrequency energized surgical scissors designed to harvest saphenous veins in cardiac bypass procedures, IMA harvesting, and general surgical applications.


On October 31st, AtriCure was established as an independent business focused on atrial fibrillation. ENABLE Medical provided contract development and manufacturing services to AtriCure.


The AtriCure bipolar ablation system was made commercially available in the U.S. for the ablation of soft tissues.


The Journal of Thoracic and Cardiovascular Surgery published the first article on AtriCure devices--"Chronic Transmural Atrial Ablation by Using Bipolar Radiofrequency Energy on the Beating Heart." The article was authored by Sunil M. Prasad, M.D., Hersh S. Maniar, M.D., Richard B. Schuessler, Ph.D., and Ralph J. Damiano, Jr., M.D.


On August 5th, AtriCure became a publicly traded company on the NASDAQ Stock Exchange. Prior to AtriCure's initial public offering, AtriCure acquired ENABLE Medical and all of its personnel, facilities and other assets.

AtriCure opened its European office in the Netherlands.


AtriCure entered the cryosurgical market when it acquired the Frigitronics cryogenic product line from CooperSurgical, Inc.

AtriCure launched the EXCLUDE trial to evaluate the safety and efficacy of the AtriClip LAA Exclusion System for occluding the left atrial appendage.


The Isolator Coolrail Linear Pen was made commercially available in the U.S. for ablation of cardiac tissue with radiofrequency energy during cardiac surgery.

The first patient was enrolled in the ABLATE Study. The primary objective of this study is to evaluate the safety and efficacy of the AtriCure Bipolar System in performing pulmonary vein isolations and the atrial “connecting lesions” of the Maze procedure.


AtriCure’s cryoICE and cryo1 cryoablation probes were made commercially available in the U.S. for the cryosurgical treatment of cardiac arrhythmias. 


The AtriClip LAA Exclusion System was made commercially available in the U.S. for the occlusion of the left atrial appendage, under direct visualization, in conjunction with other open cardiac surgical procedures.


Following successful completion of the ABLATE study, AtriCure’s Isolator Synergy ablation system became the first device approved by FDA for the treatment of persistent or longstanding persistent atrial fibrillation.


AtriCure partnered with Dr. James L. Cox and launched the Maze IV training program in the United States to educate healthcare providers on the safe and effective use of the AtriCure Isolator Synergy System in the treatment of non-paroxysmal forms of atrial fibrillation.


AtriCure expanded the Maze IV training program to Europe.


A milestone was reached as AtriCure surpassed 150,000 ablations and over 200,000 patients treated.

The Minneapolis office was also opened.

AtriCure acquired Endoscopic Technologies, Inc. (Estech), which expanded AtriCure's product portfolio with the addition of the Fusion Surgical Ablation System and a comprehensive suite of cardiac surgery instruments. As a result, AtriCure opened the San Ramon office.


Launched the availability of its cryoICE cryo ablation probe (CRYO2) to provide cryo nerve block for temporary pain management. AtriCure’s cryoICE is the first cryoablation probe made commercially available in the U.S. for the treatment of cardiac arrhythmias and for the temporary ablation of peripheral nerves to block pain.

A milestone in LAA management is reached with more than 50,000 patients worldwide having been treated with AtriClip LAA Exclusion System.

AtriCure acquired nContact Surgical, LLC., a privately held developer of innovative cardiac ablation solutions.

On November 3rd, the Cincinnati headquarters opened its newly built facility in Mason, Ohio.

AtriCure announces first patient enrolled in international Afib clinical study, Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation (CEASE-AF).


First patient enrolled in ATLAS clinical study. This observational study explores the use of the AtriClip device to decrease complications associated with Post-Operative Afib (POAF) by targeting specific cardiac surgery patient populations at the highest risk of developing POAF.

The cryoFORM cryoablation probe was made commercially available in the U.S. This probe offers increased probe flexibility to adapt to a variety of surgical ablation procedures.

A new AtriClip device, called the AtriClip PRO2 was made commercially available in the U.S and European markets. This new device has increased functionality that enhances the capability of occluding the left atrial appendage in minimally-invasive cardiac surgeries.

Gained approval for the AtriClip products and cryoICE platform in Japan.

First patient enrolled in the FROST trial. This clinical study examines the cryoICE Cryoablation Probe, CRYO2, for pain management in post thoracic procedures via intercostal cryo nerve block.

STS 2017 Clinical Practice Guidelines for Surgical Treatment of Afib changed surgical ablation at the time of structural heart surgery from a Class II to a Class I recommendation. The recommendations have gone from it is “reasonable” to do an ablation in Afib patients undergoing major types of structural heart surgery to it is “recommended” to do an ablation.


A milestone was reached as AtriCure surpassed 100,000 AtriClip LAA Exclusion System devices sold worldwide.

The AtriClip PRO•V device has been made commercially available in the U.S. The new device offers several modifications which enable easier navigation and placement when operating in minimally-invasive surgery (MIS) environments.


The AtriClip FLEX•V device was designed to improve open-chest clip placement. We strive to increase left atrial appendage management and enhance open-concomitant cardiac surgery to help patients worldwide.


First patient enrolled in the ICE-AFIB IDE trial. This clinical trial will evaluate the safety and effectiveness of AtriCure’s cryoICE Ablation System for the treatment of persistent and long-standing persistent atrial fibrillation in open concomitant cardiac surgery.

The cryoICE cryoSPHERE probe has been made commercially available in the U.S. cryoSPHERE is the first device in the cryoICE family solely dedicated to blocking pain by temporarily ablating peripheral nerves.

The Society of Thoracic Surgeons endorsed AtriCure’s Advanced Ablation Courses in the United States. The course provides surgeons and other medical professionals with a comprehensive overview of the treatment of Afib during concomitant surgery.


MO100000 marked the 100,000th production build.

aMAZE Clinical Trial completes enrollment.